Skip to content

Study · Randomized controlled trial · n = 22 · 2009

5 results

The effect of exenatide on lisinopril pharmacodynamics and pharmacokinetics in patients with hypertension.

Linnebjerg H, Kothare P, Park S, Mace K, Mitchell M

International journal of clinical pharmacology and therapeutics1 Nov 2009Cited by 11 (Europe PMC)

PMID19840529 (opens in a new tab)DOI10.5414/cpp47651 (opens in a new tab)PepBankPUB-19840529
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In hypertensive patients on lisinopril, exenatide did not significantly change diastolic blood pressure versus placebo.

    In plain wordsIn patients taking lisinopril, exenatide did not significantly change diastolic blood pressure versus placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeDiastolic blood pressure
    Study

    n = 22

    Comparator
    Placebo with lisinopril
    Analysis
    Primary
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    10 microg twice daily · subcutaneousAs given in this study (human).

    Measurements

    Diastolic blood pressure difference
    1.38 mmHg
    LS mean difference between exenatide and placebo with lisinopril (95% CI -1.41 to 4.17)

    Source sentences

    Summary
    The least squares mean differences (95% CI) between treatments were +1.38 mmHg (-1.41, 4.17) for diastolic and +1.38 mmHg (-1.95, 4.71) for systolic blood pressure.
    4 context sentences
    Summary · context
    Mean blood pressure changes were not significantly different between exenatide and placebo coadministered with lisinopril.
    Summary · context
    The primary pharmacodynamic parameters were baseline-adjusted 24-hour mean systolic and diastolic blood pressure.
    Summary · context
    22 patients with mild-to-moderate primary hypertension participated in a double-blind, randomized, placebo-controlled, 2-period, 2-sequence crossover study.
    Summary · context
    Patients on stable lisinopril therapy were randomly assigned to receive subcutaneous exenatide (10 microg b.i.d.) and placebo b.i.d. separated by at least 2 days washout period.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In hypertensive patients on lisinopril, exenatide did not significantly change systolic blood pressure versus placebo.

    In plain wordsIn patients taking lisinopril, exenatide did not significantly change systolic blood pressure versus placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeSystolic blood pressure
    Study

    n = 22

    Comparator
    Placebo with lisinopril
    Analysis
    Primary
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    10 microg twice daily · subcutaneousAs given in this study (human).

    Measurements

    Systolic blood pressure difference
    1.38 mmHg
    LS mean difference between exenatide and placebo with lisinopril (95% CI -1.95 to 4.71)

    Source sentences

    Summary
    The least squares mean differences (95% CI) between treatments were +1.38 mmHg (-1.41, 4.17) for diastolic and +1.38 mmHg (-1.95, 4.71) for systolic blood pressure.
    4 context sentences
    Summary · context
    Mean blood pressure changes were not significantly different between exenatide and placebo coadministered with lisinopril.
    Summary · context
    The primary pharmacodynamic parameters were baseline-adjusted 24-hour mean systolic and diastolic blood pressure.
    Summary · context
    22 patients with mild-to-moderate primary hypertension participated in a double-blind, randomized, placebo-controlled, 2-period, 2-sequence crossover study.
    Summary · context
    Patients on stable lisinopril therapy were randomly assigned to receive subcutaneous exenatide (10 microg b.i.d.) and placebo b.i.d. separated by at least 2 days washout period.
  3. 03HumanRandomized controlled trialPharmacokinetics

    In hypertensive patients, exenatide delayed lisinopril time to maximum concentration by 2 hours versus placebo.

    In plain wordsIn patients with hypertension, exenatide delayed the time to peak lisinopril concentration by 2 hours versus placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseLisinopril time to maximum concentration
    Study

    n = 22

    Comparator
    Placebo with lisinopril
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    10 microg twice daily · subcutaneousAs given in this study (human).

    Measurements

    Delay in lisinopril tmax,ss
    2 hours
    exenatide versus placebo with lisinopril

    Source sentences

    Summary
    Exenatide delayed the time to attain maximum lisinopril concentration (tmax,ss) by 2 hours but did not significantly alter maximum lisinopril concentration (Cmax,ss) or area under the concentration-time profile (AUCtau,ss) over the 24-hour steady-state dosing interval.
    2 context sentences
    Summary · context
    22 patients with mild-to-moderate primary hypertension participated in a double-blind, randomized, placebo-controlled, 2-period, 2-sequence crossover study.
    Summary · context
    Patients on stable lisinopril therapy were randomly assigned to receive subcutaneous exenatide (10 microg b.i.d.) and placebo b.i.d. separated by at least 2 days washout period.
  4. 04HumanRandomized controlled trialPharmacokinetics

    In hypertensive patients, exenatide did not significantly alter lisinopril maximum concentration versus placebo.

    In plain wordsIn patients with hypertension, exenatide did not significantly change peak lisinopril levels versus placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeLisinopril maximum concentration
    Study

    n = 22

    Comparator
    Placebo with lisinopril
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    10 microg twice daily · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Exenatide delayed the time to attain maximum lisinopril concentration (tmax,ss) by 2 hours but did not significantly alter maximum lisinopril concentration (Cmax,ss) or area under the concentration-time profile (AUCtau,ss) over the 24-hour steady-state dosing interval.
    2 context sentences
    Summary · context
    22 patients with mild-to-moderate primary hypertension participated in a double-blind, randomized, placebo-controlled, 2-period, 2-sequence crossover study.
    Summary · context
    Patients on stable lisinopril therapy were randomly assigned to receive subcutaneous exenatide (10 microg b.i.d.) and placebo b.i.d. separated by at least 2 days washout period.
  5. 05HumanRandomized controlled trialPharmacokinetics

    In hypertensive patients, exenatide did not significantly alter lisinopril steady-state exposure versus placebo.

    In plain wordsIn patients with hypertension, exenatide did not significantly change lisinopril exposure versus placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeLisinopril exposure
    Study

    n = 22

    Comparator
    Placebo with lisinopril
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    10 microg twice daily · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Exenatide delayed the time to attain maximum lisinopril concentration (tmax,ss) by 2 hours but did not significantly alter maximum lisinopril concentration (Cmax,ss) or area under the concentration-time profile (AUCtau,ss) over the 24-hour steady-state dosing interval.
    2 context sentences
    Summary · context
    22 patients with mild-to-moderate primary hypertension participated in a double-blind, randomized, placebo-controlled, 2-period, 2-sequence crossover study.
    Summary · context
    Patients on stable lisinopril therapy were randomly assigned to receive subcutaneous exenatide (10 microg b.i.d.) and placebo b.i.d. separated by at least 2 days washout period.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.